Index

A
Acute respiratory distress syndrome (ARDS), 282
Adenosine triphosphates (ATPs), 185
Adhesion molecules, 132, 135–136
Adipose tissue (AT), 302
AEC1. See Alveolar Type I Epithelial Cells (AEC1)
AECII. See Alveolar Type II epithelial cells (AECII)
Aerobic metabolism, 185
Aerobic respiration, 183
Airflow obstruction, 285, 288
Airway and vascular remodeling, 168
Airway obstruction, 168
Alveolar type I epithelial cells (AEC1), 5, 28
Alveolar type II epithelial cells (AECII), 28
Alveolarization, 95, 96
Alveolocapillary gas exchange, 188
American Thoracic Society (ATS) guidelines, 285
Angiopoietin-2, 142
Anti-infective agents, 87–88
Antioxidant (AO) capacity, cell resulting, 6
defense systems, 186, 187
denogogenous enzymes, 6
low-molecular weight, 7
mechanisms, 7
Antioxidant enzymes (AOEs), 327
Apoptosis, 188
Arterial oxygen saturation, 176, 178
Arterial partial pressure of O₂ (pO₂), 189
ATP-binding cassette, 118
Attention deficit hyperactivity disorder (ADHD), 285
Azithromycin, 87, 88, 330

B
Baboons, 5
BALF. See Bronchoalveolar lavage fluid (BALF)
Barotrauma, 59, 60
Bayley III scales, 193
Bi-level CPAP, 210
Biomarkers
adhesion molecules, 135, 136
anti-inflammatory cytokines, 140
CC10, 140, 141
chemokines, 133
enzymes, 139
fetal lung development, 141
inflammation, 129
inflammatory process, 130
limitations, 143
NAC, 140
oxidative stress, 139
preterm infants, 130
VEGF, 141
Bombesin-like peptide (BLP), 14
Bone marrow (BM), 302
BOOST II trial, 194
Brain oxygenation, 191
Bronchial hyperresponsiveness, 282, 284–288
Bronchoalveolar lavage fluid (BALF), 8, 60, 130
Bronchopulmonary dysplasia (BPD), 3, 79, 167, 223, 259, 281
acinar development, 156
adult lungs, 157
airflow limitations, 282
airway growth, 160
alveolar and microvascular remodeling, 149
alveolar growth abnormalities, 160

© Springer International Publishing Switzerland 2016
V. Bhandari (ed.), Bronchopulmonary Dysplasia, Respiratory Medicine,
DOI 10.1007/978-3-319-28486-6
Bronchopulmonary dysplasia (BPD) (cont.)
- alveolar pathology, 157
- alveolar simplification and dysmorphic microvasculature, 157
- alveolarization and pulmonary vascular development, 56
- alveolarization and vascular development, 69
- autopsy findings, 156
- bronchial hyperresponsiveness, 282
- bronchial lesions or alveolar septal fibrosis, 161
- cellularity and fibrosis, 156
- characterized, 169
- chronic fibroproliferative stage, 154
- chronic lung disease, preterm infants, 149, 150
- chronic respiratory disease, 281
- clinical presentation, 109
- CNVs, 111
- definition, 283
- degree of prematurity, 169, 177
- description, 243–247
- diagnostic definition, 167, 169–170
- elastic fiber architecture, 154
- epidemiology of, 168–169
- exogenous surfactant, 156
- exogenous surfactant and antenatal steroid administration, 149
- fetal inflammatory response syndrome, 58–59
- fibroproliferative lung injury, 160
- fibroproliferative response, 156
- genetic association, 112
- genetic variants, 111, 113
- haplotype, 116
- HapMap project, 112
- human genome, 111
- hyperexpansion and atelectasis, 154
- in vitro and in vivo data, 55
- incidence of, 176
- infection/sepsis, 328
- inflammation-induced influx, 326
- intra-amniotic infection and inflammation, 55
- long-term damage, 154
- lung function studies, 159, 160
- lung morphogenesis, 149
- lung pathology, 55
- mechanical ventilation, 149
- miRNA, 117
- morphometric and biochemical techniques, 157
- mycoplasma (see Mycoplasma)
- neutrophils and macrophages, 68
- newborn animal models, 4–5
- and nitrogen-free radicals, 188
- nutrition (see Nutrition)
- obstructive bronchiolar lesions, 154
- old BPD vs. new BPD, 282
- and O2 therapy, 185
- oxidative stress, 115
- oxidative stress antioxidants, 327
- oxygen requirement at postnatal ages, 172–175
- oxygen supplementation, 170–172
- pathogenesis (see Hyperoxia)
- pathophysiology, 109
- pediatric scientific community, 281
- perinatal and neonatal conditions, 161
- pharmacological interventions, 56
- population at risk, 177–178
- postcanalicular lung remodeling, 157
- postcanalicular lungs, 161
- postnatal factors, 55
- pre and postnatal pro-inflammatory conditions, 58, 68
- precapillary arteriovenous anastomoses, 157
- premature infants, 299
- prematurity, 281
- prematurity-associated lung injury, 56
- prematurity-associated lung pathology, 150
- preterm infants, 156, 160
- pulmonary arteries and intra-acinar arterioles, 156
- pulmonary function in survivors (see Preterm birth)
- pulmonary hypertension (see Pulmonary hypertension (PH))
- pulmonary interstitial emphysema, 154
- pulmonary microvasculature, 157
- RDS, 55, 169, 281
- respiratory distress syndrome (RDS), 154
- septal interstitium, 154
- severe forms of, 168, 169
- severity, 288–292
- severity classification, 175–176
- SPOCK2 gene, 114
- surfactant, 149, 327–328
- susceptibility, 110
- treatment, 336
- vascular and airway smooth muscle cell development, 55
- vascular hypothesis, 157
- Vitamin D, 115
- wide spectrum, 150
- Brown’s meta-analysis, 192
C
Calcium (Ca), 232
Caspases, 10
Cell death
caspases and components, 10
and hyperoxia-induced lung cell injury, 9–10
Cell transplantation, 299
mesenchymal stem cells (MSCs)
(see MSCs transplantation)
stem (see Stem cell transplantation)
Cerebral palsy, 177
Chemokines, 133–135
Chest radiographs
bubbly lung, 245
degree of hyperexpansion, 247
development of BPD, 247
differential diagnosis, 249
digital, 247
features, 247
granular pattern, lung parenchyma, 244
honeycomb or spongelike appearance, 245
immature lung, 247
infancy to adulthood, 248–249
leaky lung syndrome (LLS), 244, 248
peri- and neonatal care, 247
premature infants, 248
scoring of chest CT scan, 250
scoring systems, 247
structural changes, lungs, 247
type 1 and type 2 diseases, 247
Children’s Interstitial Lung Disease (ChILD) Research Network, 157
Chorioamnionitis (CA), 79, 85, 86
adverse pro-inflammatory conditions, 57
animal experiments, 57
chronic inflammatory process, 57
definition, 56
gestation-independent effect, 57
lipopolysaccharide (LPS), 57
maturational effect, 57
microbial colonization, 57
microbial invasion/pathological processes, 56
microorganisms, 56
pro-inflammatory cytokines, 56
Ureaplasma spp., 56
uterine infection, 56
Chronic obstructive pulmonary disease in adult life, 94
airway obstruction, 96
asthma and wheezing, 95
C/EBPs, 98
environmental exposures, 100
lung function, 95
parental smoking, 100
pathology, 93
prevalence, 93
Clara Cell 10 Protein (CC10), 335, 337
Clara cell secretory protein 10 (CC10), 140
Closed-loop FiO2 control system (CLiO), 194
Continuous positive airway pressure (CPAP), 60, 200
BPD/death rates, 316
Bubble, 200
INSURE technique, 206–207, 316
intubation group, 315
modern interfaces, 201
neonatal ventilators, 200
observational studies, 203–204
physiological effects, 200
post-extubation period, 201
pressure generation and delivery, 200–201
pressure-generating devices, 200
vs. supplemental oxygen, 201–202
weaning preterm infants, 207
Copy-number variations (CNVs), 111
Cord clamping, 190
CPAP. See Continuous positive airway pressure (CPAP)
Curcumin, 334
Cytokine-induced neutrophil chemoattractant-1 (CINC-1), 11
Cytokines, 10, 11, 130

D
Dioxygen, 185
Docosahexaenoic acid (DHA), 332–333
fetal lung growth, 231
levels, time of birth, 232
parenteral lipid administration, 232
source, 232

E
Early-onset sepsis (EOS), 59
EGFR. See Epidermal growth factor receptor (EGFR)
ELBW. See Extremely low-birth weight (ELBW)
Endotracheal ventilation, 200, 201, 203
EOS. See Early-onset sepsis (EOS)
Epidermal growth factor receptor (EGFR), 35
Erythropoietin (EPO), 188
Eunice Kennedy Shriver National Institute of
Child Health and Human
Development (NICHD), 169
Extracellular SOD (ecSOD), 7
Extremely low-birth weight (ELBW), 39, 60, 183
Extremely preterm infants, 223
   nutritional support (see Nutritional support
   of extremely preterm infant)
   potential effects of undernutrition, 224

F
FEV1/forced vital capacity (FVC) ratio, 285, 290, 291
FRC. See Functional residual capacity (FRC)
Free radicals, 185
Functional residual capacity (FRC), 33, 200

G
Gene expression, 116
Genetic pathway analyses, 116–117
Genetic susceptibility, 69
Glutathione (GSH), 187

H
Hedgehog interacting protein (HHIP), 98
Hepatocyte growth factor (HGF), 14, 301, 302
Heterodimeric transcription factor, 188
High-flow nasal cannulae (HFNC), 211
   vs. nasal CPAP, 211–214
   vs. NIPPV, 212–213
   for weaning from CPAP, 214–215
High-resolution computed tomography
   (HRCT)
   adulthood, 254
   BPD patients, 250
   early teenage to adolescence, 246, 253
evaluation, 249
   infancy and early childhood, 251–253
   lung abnormalities, 249
   multifocal areas, 249
   pulmonary parenchyma, 249
   respiratory dysfunction, 249
   scoring, 252
   scoring systems, 250, 251
   severity of BPD, 249

I
HIPERSPACE trial, 213
Host immune response, 81–82
Hyaline membrane disease, 153, 154
Hyperoxia, 5–8, 188, 194
   BLP, 14
   CINC-1, 11
genetic and environmental factors, 3
   HGF, 14
   IFNγ, 12
   IL-1, 10
   IL-10, 11
   IL-6, 10–11
   IL-8, 11
   KGF, 11
   lung injury, mechanism (see Lung injury)
   MCP-1, 11
   MIF, 13
   MMP9, 12
   MT, 15
   newborn animal models, 4–5
   pathology of new BPD, 4
   S1P, 15
   SOD, 15–16
   STOP-ROP trial, 3
   TGFβ, 12–13
   TNFα, 13
   VEGF, 13–14
Hypertension, 259
   pulmonary (see Pulmonary hypertension
   (PH))
Hypoxemia, 194
Hypoxia response elements (HREs), 188
Hypoxia-inducible factor 1α (HIF-1α), 6, 184, 189

ICAMs. See Intercellular adhesion molecules
   (ICAMs)
IGF. See Insulin growth factor (IGF)
   Infants, 259, 299, 300, 303–307
   Inflammatory cells, 138
   Inhaled nitric oxide (iNO), 269, 329
   Insulin growth factor (IGF), 41
   INSURE technique, 203, 206–207
   Intercellular adhesion molecule-1 (ICAM-1), 136
   Intercellular adhesion molecules (ICAMs), 62
   Interferon gamma (IFNγ), 12
   Interleukin-1 (IL-1), 10
   Interleukin-10 (IL-10), 11
   Interleukin-18 receptor 1 (IL18R1), 114
   Interleukin-6 (IL-6), 10–11
   Interleukin-6 (IL-6) concentration, 326
   Interleukin-8 (IL-8), 11
Index

Intrauterine infection models, 85–87
  detection, 88
  and lung injury, 81
Intraventricular hemorrhage (IVH), 320
Intubation
  BPD, 315
  CPAP, 315
  and mechanical ventilation, 318
Invasive mechanical ventilation
  AECI, 28
  AECII, 28
  alveolar development and disruption, 27
  alveolar septation, 39–41
  alveolar–capillary permeability, 29–31
  animal models, 42–43
  cell proliferation, differentiation and apoptosis, 41–42
  chronic lung disease, 27
  EGFR, 41
  ELBW, 39
  endothelial cells, 29
  fibroblasts, 29
  lung development, 39
  lung inflammation and injury, 27
  macrophages, 29
  mechanical injury, 28
  neutrophils and macrophages, 31–32
  saccules, 39
  VEGF, 42
  VILI, 27
  clinical characteristics of BPD, 289, 290
dysynaptic/unequal lung growth, 291
  early childhood, 283
  lung function measurements of BPD subjects, 290, 291
  mechanical ventilation and oxygen therapy, 292
  mild disease, 289
  neonatal respiratory illness, 291
  NICHD review, 292
  NIH consensus, 289
  oxygen dependency, 288
  oxygen therapy, 290
  pathogenesis, 288
  postnatal risk factors, 288
  retrospective cohort, 290
  retrospective study, 289
  supplemental oxygen, 289
  LOS. See Late-onset sepsis (LOS)
Lung development
  alveolar stage, 153
  canalicular stage, 151
  embryonic stage, 150
  fetal, 150, 151
  organogenesis, 150
  pseudoglandular reflect, 151
  pseudoglandular stage, 151
  saccular (terminal sac) stage, 152, 153
  Lung function, 100
  Lung injury, 5–10, 168, 170, 180
  hyperoxia
    airway epithelial layer thickness and
    airway smooth muscle area, 8
    airway epithelium serves, 8
    alveolar type II epithelial cells, 7
    cell injury and cell death, 9–10
    childhood wheezing disorders, 8
    HIF-1α, 6
    human neonates, 7
    macrophage and PMN infiltration, 8
    MnSOD/ECsOD, 7
    Nox, 6
    Nrf2, 7
    O2, 5
    oxidative stress, 6
    oxygen-induced injury, 6
    P53, 7
    pulmonary microvascular endothelial cells, 5
    RNS, 5–7
    ROS, 5–7
    tracheal aspirates and bronchoalveolar lavage (BAL) fluid, 8
    VEGF, 6

K
Keratinocyte growth factor (KGF), 11
Krebs von den Lungen-6 (KL-6), 142

L
Late-onset sepsis (LOS), 59
Less invasive surfactant administration (LISA)
  and BPD, 318–321
  death rates, 319
  endotracheal tube, 317
  Magill forceps, 316
  and mechanical ventilation, 317–318
  safety, 321
  sedation/premedication, 316
  VLBW infants, 322
Long-chain polyunsaturated fatty acids
  (n-3 LCPUFAs), 231, 236
Long-term consequences of preterm birth
  ADHD, 292
  adulthood, 284
  categories of disease severity, 289
Macrophage migration inhibiting factor (MIF), 13
Macrophages, 134
Magnetic resonance imaging (MRI)
early changes, emphysema, 255
lack of radiation exposure, 254
low-density cyst-like focal abnormalities, 255
preterm infants, 255
severe BPD, 256
T1-weighted and proton density-weighted images, 255
MAPK. See Mitogen-activated protein kinase (MAPK)
Matrix metalloproteinase 9 (MMP9), 12
Mechanotransduction
EGFR, 35
gene expression, 39
growth factor receptors, 38
inflammatory response, 35
integrins–focal adhesions–cytoskeleton, 37–38
intracellular signaling pathways, 38
ion channels, 36, 37
mechanical deformation, 35
transcription factors, 38, 39
Medical Research Council (MRC) dyspnea score, 285
Melatonin (MT), 15
Mesenchymal stem cells (MSCs), 305, 333
adult tissues, 302
AT, 303
BM, 302, 303
characteristics, 302
donor age, 303
gestational tissues, 303
transplantation (see MSC transplantation)
umbilical cord and placental tissue, 303
Migration inhibitory factor (MIF), 137
Mitochondrial manganese SOD (MnSOD), 7
Mitogen-activated protein kinase (MAPK) signaling, 328
Mitogen-activated protein kinases (MAPK), 12, 37
Molecular mechanisms
alveolar capillary permeability, 65–66
alveolarization and angiogenesis, 66–67
cellular and endothelial interaction, 62
cellular and humoral mediators, 61
chemotactic and chemokinetic factors, 62
inflammation, 68
oxygen radicals and proteolytic mediators, 65
pro- and anti-inflammatory cytokines, 62–63
PRRs, 64–65
repair mechanisms and growth factors, 67
stem cell therapy, 68
Monocyte chemoattractant protein-1 (MCP-1), 11
MSC transplantation
long-term safety and outcomes, 306
optimal dose, 305
optimal timing, 305–306
phase I clinical trial, 307
Multiple-banded antigen (MBA)
size variants, 85
ureaplasmal cell surface MBA protein, 81
virulence factors, 80
Mycoplasma, 79, 82–87
animal models
human BPD, 82
intrauterine infection models, 85–87
mycoplasma infections, 82–84
pneumonia models, 82–84
Ureaplasma infection, 82, 85
anti-infective agents, 87–88
host immune response, 81–82
microbiology, 80
Mycoplasma hominis (see Mycoplasma hominis)
Ureaplasma parvum (see Ureaplasma parvum)
Ureaplasma urealyticum (see Ureaplasma urealyticum)
virulence factors, 80–81
Mycoplasma hominis
amniotic fluid isolates, 81
genitourinary tract commensals, 79
hydrolyzes arginine, 80
respiratory samples, 79
Myelin basic protein (MBP), 306
NAD phosphate (NADP), 185
NADPH oxidase (Nox), 6
Nasal cannula (NC) flow, 178
Nasal continuous positive airway pressure (nCPAP), 195
Nasal intermittent positive pressure ventilation (NIPPV), 204, 329
history, 208
in post-extubation period, 209
physiological effects, 208, 209
studies, 209–210
National Centre for Biotechnology Information (NCBI), 111
National Institute of Child Health and Human Development (NIHCD), 283
Index

National Institutes of Health (NIH), 170, 175, 289
Necrotizing enterocolitis (NEC), 187, 331
Neonatal European Study of Inhaled Steroids (NEUROSIS), 332
Neonatal intensive care unit (NICU), 183
Neonatal Oxygenation Prospective Meta-analysis Collaboration study (NeOProM), 193
Neonatal ventilators, 200
Neonatal-Onset Respiratory Disease, 117–119
ABCA3 gene, 118
SFTPB gene, 118
SFTPC gene, 119
TTF1, 119
Neurally adjusted ventilatory assist (NAVA) mode, 209
Newborn animal models
hyperoxia, 4, 5
Newborns
lung disease, 13
mice, 7
Nrf2−/− mice, 7
SOD, 16
with RDS, 15
treatment, 12
NICHD Neonatal Research Network, 169, 176, 178, 179
Nicotinamide adenine dinucleotide (NAD), 185
Nicotinamide adenine dinucleotide phosphate (NADPH), 328
Nitrogen-free radicals, 188
Nuclear factor kappa B (NF-κB), 187, 327
Nuclear factor-erythroid 2-related factor 2 (Nrf2), 7
Nutrition, 225–228, 235–236
calcium (Ca), 232–233
carbohydrates, 230
degree of critical illness in AGA infants
energy and fluid intake, 226
outcome variables, 227
development of BPD, 224, 225
extremely preterm infant (see Nutritional support of extremely preterm infant)
fluids usage, 229–230
guidelines (see Standardized feeding guidelines)
inositol, 230
magnesium (Mg), 233
NICU, 223
phosphorus (P), 233
post-discharge (see Post-discharge nutrition) protein, 231
selenium (Se), 235
triglycerides and fatty acids, 231–232
Vitamin A, 233–234
Vitamin E, 234, 235
Nutritional support of extremely preterm infant
analysis, 225
daily energy and fluid intakes, first 3 weeks, 225
mediation framework, 226
severity of critical illness for AGA infants, 225
SGA infants, 226
O
O2 load, 191
Oxidative phosphorylation, 185
Oxidative stress, 187
Oxidative stress biomarkers, 192
Oxidized glutathione (GSSG), 191
Oxygen
and mechanical ventilation, 14
oxygen-induced injury, 6
ROS, 5
saturation, 3
STOP-ROP trial, 3
Oxygen requirement
at 36 weeks postmenstrual age, 173–175
day 28, 172–173
during first 4 weeks, 170–171
for more than 28 days, 172
Oxygen Supplementation. See Supplemental oxygen

P
Paracrine effects, 301
Paracrine mediators, 301, 302
Patent ductus arteriosus (PDA), 169
Pattern recognition receptors (PRRs), 64, 81
PCNA. See Proliferating cell nuclear antigen (PCNA)
Pediatric Academic Societies (PAS) annual meeting, 192
Pentoxifylline, 330–331
Perinatal care, 183
Periventricular leukomalacia (PVL), 187
Peroxisome Proliferator-Activated Receptor gamma Agonists (PPARγ), 334
Phosphodiesterase inhibitors, 335
Phosphorus (P), 233
Pneumonia models, 82–84
Polyunsaturated fatty acids (PUFA), 187
Positive end expiratory pressure (PEEP), 208
Post-discharge nutrition
anthropometric, 235
BPD, 236
management, very low birth weight
infants, 235
NICU, 235
planning, 235
preterm infants, 235
primary care pediatrician, 235
Postnatal risk factors
hyperoxia and hypoxia, 60–61
infection, 59
mechanical ventilation, 59–60
Preductal pulse oximetry (SpO₂), 189
Premature, 299, 300, 303, 305, 306
Premature infants, 167, 169, 173, 180
oxygen dependency, 172
with respiratory failure, 168
respiratory control function, 178
supplemental oxygen, 170
Prematurity, 150, 157, 160
consequences, 183
lung development, 183
Prenatal steroid therapy, 168
Prenatal steroids, 4
Preterm, 95, 99
Preterm birth, 283–284
BPD (see Bronchopulmonary dysplasia
(BPD))
bronchial hyperresponsiveness, 285–288
bronchodilator response, 286
demographic and clinical information,
285, 286
FEV₁/FVC ratio, 285
hospital discharge diagnosis, 284, 285
long-term respiratory outcomes
(see Long-term consequences of
preterm birth)
methacholine challenge, 287
MRC dyspnea score, 285
pulmonary function test, 285
pulmonary lung function, 285, 287
SF-36v2, 285
SGRQ, 285
Preterm infants, 315, 316, 319, 321
chorioamnionitis, 62
lung pathology, 55
oxygen saturation, 60
TNF-α positive macrophages, 63
Proinflammatory cytokines, 136–138
Proliferating cell nuclear antigen
(PCNA), 42
Prolyl-hydroxylase enzymes (PHD1–3), 188
Prostacyclin derivatives, 271
PRRs. See Pattern recognition receptors (PRRs)
Pulmonary, 259
hypertension (see Pulmonary
hypertension (PH))
Pulmonary hypertension (PH), 261–264,
269–271
artery pressure measurement, 260
biomarkers, 268
cardiac catheterization, 266, 267
chronic respiratory diseases, childhood, 259
clinical features, 265
development, 262
echocardiographic diagnosis, 266
echocardiography, 265, 266
ELBW infants, 260
heterogeneity and variability, 273
intra- or extra-cardiac shunts, 261
LVDD, infants, 265
management, 271–273
mimic, 265
prevalence, 260
PVD (see Pulmonary vascular disease
(PVD))
risk, anesthesia, 267
risk, growth-restricted infants, 261
tracheobronchomalacia, 267
treatments, infants and children, 268
vasoconstriction, 268
vasodilators (see Pulmonary vasodilators)
vasorelaxation, 269
vein stenosis, 265
VLBW infants, 259
Pulmonary hypertension in infants, 168
Pulmonary vascular disease (PVD), 259
alveolarization, 261
alveologenesis and gas exchange, 264
angiopoietin (ANG)/Tie-2 ligand/receptor
system, 263
damage and thickening of pulmonary
circulation, 262
endothelial monocyte-activating
polypeptide II (EMAP II), 262
endothelial nitric oxide synthase (eNOS), 264
hypoxia-inducible factor-1alpha
(HIF-1alpha), 263
low-density lipoprotein receptor-related
protein 5 (LRP5), 264
noxious stimuli, 261
nuclear factor kappa B, 263
pathogenesis, 261
Tie2 signaling, 264
vascular endothelial growth factor
(VEGF), 262
vasodilation and vasoconstriction, 261
Pulmonary vascularization bed, 184
Pulmonary vasodilators
do endothelin 1 (ET-1), 270
doi NO, 269
do oxygen therapy, 269
do prostacyclin (PGI2, 271
do sildenafil, 270
Pulse oximeter, 194

R
Radiology of BPD, 247, 249, 254
do acute respiratory distress, 243
do adolescence/adulthood, 256
do chest (see Chest radiographs)
do chronic disease, 245
endo HRCT technique (see High-resolution computed tomography (HRCT))
do MRI (see Magnetic resonance imaging (MRI))
do period of regeneration, 244
endo syndrome, 243
do transition to chronic disease, 244
Randomized controlled trials (RCTs), 207, 329
RDS. See Respiratory distress syndrome (RDS)
do Reactive nitrogen species (RNS), 186
endo Reactive oxygen species (ROS), 139–140, 185, 186
endo receptor for advanced glycation end products (RAGE), 98
endo Receptor tyrosine kinase (RTK) receptors, 13
do regulated on activation, normal T cell expressed and secreted (RANTES), 135
endo Respiratory distress syndrome (RDS), 55, 168, 200
endo Respiratory failure in infants, 167–169
endo Respiratory health, 285, 287, 288, 292
endo Respiratory Health Survey, 284
endo Resuscitation, 189, 190
endo Retinopathy of prematurity (ROP), 187

S
Saint George’s Respiratory (SGRQ) questionnaires, 285
endo Saugstad’s meta-analysis, 193
endo Secretory leukocyte protease inhibitors (SLPIs), 139
endo Selenium (Se), 235
endo SF-36v2, 285
endo Sildenafil, 270
endo Single nucleotide polymorphisms (SNPs), 81, 111
endo Smoking, 93, 100
endo Solithromycin, 87
endo Sphingosine kinase 1 (SphK-1), 15
endo Sphingosine-1-phosphate (S1P), 15
endo Standardized feeding guidelines
endo caloric requirements, 229
do clinical evaluation, 229
do colostrum/donor milk, 228
do development, 228
do enteral nutrition, 229
do evidence-based strategy, 228
do exceptions and non-exceptions, 228
do extremely preterm infants, 228
do implementation, 229
do measurements, growth, 229
endo nutritional practices, 228
do parenteral fluid support, 228
do reduction, growth failure, 229
do total parenteral nutrition (TPN), 228
endo TPN, 228
endo StarSync® module, 208
endo Stem cell therapy, 299
do exogenous administration, 299
endo MSCs (see Mesenchymal stem cells (MSCs))
do transplantation (see Stem cell transplantation)
endo Stem cell transplantation, 302
endo engraftment and differentiation, 300–301
endo EPCs, ECFCs, 304
endo ESCs, 304
endo MSCs (see Mesenchymal stem cells (MSCs))
do paracrine effects, 301
endo paracrine mediators, 301, 302
do therapeutic potential, 300
endo UCB MNCs, 303, 304
endo Steroids
endo hydrocortisone, 332
endo inflammation, 331
endo intestinal perforation, 331
endo neurodevelopmental side effects, 332
endo short-term side effects, 331
endo treatment, 331
endo Stretch stress
endo animal studies, 328
endo hypoxia, 328
endo noninvasive ventilation approach, 328
endo Superoxide dismutase (SOD), 15–16, 327
endo Supplemental oxygen, 170, 171, 180
endo and premature infants, 170
endo cumulative duration, 172
endo indicator of lung disease, 176
endo need for, 176
endo Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP) trial, 3
Surfactant, 202
Surfactant protein-A (SP-A)-deficient mice, 84
surfactant proteins, 118
Synchronized NIPPV (SNIPPV), 208
vs. NCPAP, 208
pressure generation and delivery, 208–209

T
The Cochrane Review, 331
Thyroid transcription factor-1 (TTF1), 119
Tissue inhibitor of metalloproteases (TIMPs), 138
TLRs. See Toll-like receptors (TLRs)
Toll-like receptors (TLRs), 64
host immune response, 81
Tracheobronchomalacia, 272
Transforming growth factor (TGF), 141
Transforming growth factor beta (TGFβ), 12–13
Transient receptor potential vanilloids (TRPV), 37
TRPV. See Transient receptor potential vanilloids (TRPV)
Tumor necrosis factor alpha (TNFα), 13, 187

U
UCB MNCs, 303, 304
Ureaplasma parvum
anti-infective agents, 87–88
genitourinary tract commensals, 79
intrauterine infection models, 85–87
pneumonia models, 82–84
serovar, 80
wild-type mice, 84
Ureaplasma urealyticum
anti-infective agents, 87–88
genitourinary tract commensals, 79
intrauterine infection models, 85–87
pneumonia models, 82–84
serovars, 80

V
Vascular cell adhesion molecules (VCAMs), 62
Vascular endothelial growth factor (VEGF), 13–14, 42, 137, 184, 189, 301, 302
lung injury, 6
VCAMs. See Vascular cell adhesion molecules (VCAMs)
VEGF. See Vascular endothelial growth factor (VEGF)
Venous cord blood, 191
Ventilator-induced lung injury (VILI), 27
air–liquid interfaces, 33
alveolar epithelial barrier function, 34
alveolar epithelial plasma membrane stress failure, 34
atelectrauma, 33
biotrauma, 33
calcium, 34
deformation-induced remodeling, 33
endothelial and epithelial barriers, 35
epithelial and endothelial cells, 33
factors, 33
FRC, 33
heterogeneity, 33
lung volumes, 33
lysosomes, 34
mechanical strain, 32
plasma membrane, 34
preterm lambs, 33
shear stress, 32
surfactant-deficient lung, 33
vesicular lipid trafficking, 34
volutrauma, 33
Very low birth weight (VLBW), 192, 282, 284, 288, 289, 325
VILI. See Ventilator-induced lung injury (VILI)
Virulence factors
ammonia, 80
MBA, 80
PAMP, 80
U. parvum serovar 3 clinical strain SV3F4 genome, 80
Ureaplasma spp., 81
ureaplasmal, 80
Vitamin A
administration, 234
and iNO, 234
benefits, 234
deficiency, preterm infants, 233
prevention, 234
risk of BPD, 234
storage and preparation, 234
supplementation, ELBW infants, 233
Vitamin D (VD), 115, 333
Vitamin E, 234

W
Weaning preterm infants, 207
Wilson–Mikity syndrome, 153
Window of vulnerability, 58, 69